Business Wire

CA-VELODYNE-LIDAR,-INC.

31.8.2021 12:50:09 CEST | Business Wire | Press release

Share
Velodyne Lidar and MOV.AI Partner to Provide Autonomous Solutions for Industrial and E-Commerce Robotics

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) and MOV.AI today announced the companies are collaborating to provide robot manufacturers with enterprise-grade automation solutions, including mapping, navigation, obstacle avoidance and risk avoidance. The MOV.AI Robotics Engine PlatformTM , combined with Velodyne’s lidar sensors, addresses the growing demand for automation in dynamic collaborative environments such as e-commerce, logistics, manufacturing and hospitals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005234/en/

The MOV.AI Robotics Engine PlatformTM , powered by Velodyne’s Puck™ lidar sensors, delivers advanced tools that allow autonomous mobile robots (AMR) manufacturers and integrators to address the challenges of safely moving in changing and unstructured environments like material handling and warehouse logistics. These markets are being driven by the dramatic growth of e-commerce. For instance, the pandemic helped propel U.S. online sales to $791 billion in 2020, up 32 percent from the prior year, according to the U.S. Department of Commerce .

The Robotics Engine Platform helps AMR manufacturers quickly develop and deploy robots that can operate in dynamic environments in which humans, manual machines and robots work side by side. The platform leverages the performance and reliability of the Puck sensor to allow mobile robots to traverse outside controlled situations and safely function in unfamiliar and unpredictable settings. The Puck’s compact form factor enables it to be embedded easily into robots. The sensor delivers high accuracy in complex indoor and outdoor environments.

The MOV.AI ROS-based Robotics Engine PlatformTM provides AMR manufacturers and automation integrators with the enterprise-grade tools they need for advanced automation. It includes a visual Integrated Development Environment (IDE), off the shelf algorithms and integrations, fleet management, flexible interfaces with warehouse environments such as ERP and WMS, and cyber-security compliance. The solution provides ±2 cm accuracy for a 65 percent dynamic environment.

“Adding MOV.AI and Velodyne technologies to TUGBOT.ai provided our robot with an off-the-shelf, high-accuracy navigation and localization solution for the high and dynamic environments where we are deploying our AMRs,” said Fernando Freitas, CEO at RoboSavvy, manufacturer of the AMR TUGBOT.ai. “Using lidar-based SLAM enables TUGBOT.ai to navigate safely among people and other vehicles with accurate and consistent performance.”

“MOV.AI’s mission is to simplify collaborative robot development and to provide AMR manufacturers and integrators with everything they need to develop and operate great robots,” said Motti Kushnir, MOV.AI’s CEO. “Through the collaboration with Velodyne, we are able to offer our customers advanced SLAM navigation powered by the Puck, one of the world’s leading lidar sensors. Use of our Robotics Engine Platform allows AMR manufacturers to quickly implement state-of-the-art navigation, while leaving them the ability to customize it to their needs.”

“We are very excited about the collaboration with MOV.AI and integration of our lidar sensors into the Robotics Engine Platform, including future expansion to our solid state Velarray and Velabit products,” said Erich Smidt, Executive Director of Europe, Velodyne Lidar. “There is a growing demand for automation and integration of our sensors into collaborative robots. We see extensive potential in this space, with the global AMR market size is expected to reach USD 8.70 billion in 2028, with a CAGR of 23.7 percent from 2021 to 2028, according to Fortune Business Insights . Partnering with MOV.AI can enable us to bring safety, efficiency and sustainability into the industrial sector on a large, global scale.”

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .

About MOV.AI

MOV.AI is changing AMRs as we know them.

It provides AMR manufacturers and integrators with the tools they need to create enterprise-grade robots quickly, allowing users to benefit from automation products that are as flexible as the age we live in.

MOV.AI is a Robotics Engine platform based on ROS and packaged in an intuitive web based interface. It contains everything needed to build, deploy and operate intelligent robots. MOV.AI completely changes the way Autonomous Mobile Robots are developed, in terms of time to market, cost and flexibility.

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Link:

ClickThru

Social Media:

https://www.facebook.com/VelodyneLidar/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye